DCTD Drug Development Project Management

DCTD 药物开发项目管理

• 批准号: 8654757
• 负责人: DAVID HEIMBROOK
• 金额: $ 2077.28万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-26 至 2018-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8654757
• 关键词: Academia; Address; Antineoplastic Agents; Area; Award; Biological; Biological Assay; Biology; Biotechnology; Businesses; Charge; Chemicals; Chemistry; Clinic; Clinical; Clinical Research; Clinical Trials; Complex; Contracts; Data; Development; Developmental Therapeutics Program; Division of Cancer Treatment and Diagnosis; Drug Discovery Groups; Ensure; Evaluation; Funding; Generations; Goals; Government; Grant; Human; Investigation; Investments; Joint Ventures; Joints; Lead; Malignant Neoplasms; Medicine; Mission; Molecular; Monitor; NCI Center for Cancer Research; New Agents; Office Management; Oncologist; Oncology Group; Patient Care; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phenotype; Private Sector; Process; Research; Research Activity; Research Infrastructure; Research Support; Resources; Signal Pathway; Site; Staging; Structure; Structure-Activity Relationship; Synthesis Chemistry; Technology; Testing; Therapeutic; Therapeutic Human Experimentation; Vision; Work; analog; anticancer research; bone; cancer diagnosis; cancer therapy; clinical application; design; drug development; drug discovery; experience; flexibility; high throughput screening; innovation; molecular oncology; novel; oncology; programs; research clinical testing; screening; small molecule; therapeutic development; tool

The Chemical Biology Consortium is being developed by NCI's Division of Cancer Treatment and Diagnosis (DCTD), in conjunction with the Center for Cancer Research (CCR) and the NCI Office of the Director (OD) to facilitate the discovery and development of new agents to treat cancer. It is envisioned that initiation of this consortium will provide cutting-edge chemical tools for probing complex signaling pathways and will serve as the starting point for the elaboration of first-in-class targeted therapies. The CBC will be an integrated research consortium at the interface of chemical biology and molecular oncology that will, working with various programs within DCTD and CCR, establish an iterative cancer drug discovery group on the scale of a small biotechnology concern. The goal of the CBC will be to focus on unmet therapeutic needs in oncology that are not currently addressed by the private sector. The long-term vision of the CBC is to bridge the gap between basic scientific investigation and clinical research supported by the NCI as the first step in re-establishing the NCI as a world leader in the area of innovative cancer therapeutics discovery. To address this challenge and to ensure that NCI re-emerges as a strong and flexible player in the national cancer therapeutics discovery arena, we propose to develop a national effort in coordinated cancer drug discovery that unites academic and small biotechnology chemical biology and molecular oncology groups with the later-stage drug development resources of the NCI's Developmental Therapeutics Program (DTP). This unique effort will: 1. Focus on the identification of novel targets, and the development of new molecules to interrogate those targets and serve as lead structures around which potential drugs can be designed and tested by a restructured NCI therapeutics pipeline. This will be accomplished, in part, by establishing a consortium of chemists, chemical biologists, and molecular oncologists, formed in recognition of the increasing need for a highly interdisciplinary and creative team research effort in drug discovery, that will propel the NCI into the era of personalized therapeutic cancer medicine. These teams will be formed with funding through the use of NCI contracts, NCI-SAIC subcontracts, or NCI grants mechanisms, whichever is most expedient and appropriate to the scientific expertise required. 2. Establish an iterative drug discovery effort that will coalesce all segments of the current NCI therapeutics research activity, so that the development of promising chemical leads into bone fide clinical candidates can be accelerated 3. Build an enhanced, and robust drug pipeline with the goal of producing a new clinical agent for first-in-human clinical testing in the fourth quarter of 2009 The integrated process outlined here will allow NCI to maximize the return on its investment in molecular oncology over the past decade by consolidating and coordinating the essential chemical and biological technologies that are available and necessary for therapeutics development. This initiative will also streamline the therapeutics development workflow for chemists and biologists in academia and small business by enhancing the scientific infrastructure available to move their molecules along the entire drug development pipeline into first-in-human clinical trials. We believe that the NCI Chemical Biology Consortium will provide the new strategic approach that is required for NCI to re-establish itself as a world leader in anticancer drug discovery and development.

化学生物学联盟是由NCI癌症治疗和诊断部（DCTD）与癌症研究中心（CCR）和NCI主任办公室（OD）联合开发的，旨在促进癌症治疗新药的发现和开发。预计该联盟的启动将为探测复杂信号通路提供尖端的化学工具，并将作为阐述一流靶向治疗的起点。CBC将是一个集化学生物学和分子肿瘤学于一体的综合研究联盟，它将与DCTD和CCR内的各种项目合作，建立一个小型生物技术公司规模的癌症药物研发小组。CBC的目标是专注于目前私营部门未满足的肿瘤学治疗需求。CBC的长期愿景是弥合NCI支持的基础科学研究和临床研究之间的差距，作为将NCI重新建立为创新癌症治疗发现领域的世界领导者的第一步。